Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PARG | Q86W56 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932063 | 0.84 | SMN1; SMN2 (0.59) | KMT2AALDH1A1SMN1; SMN2DPP4DPP7 | |
| SCHEMBL3683615 | 0.83 | KMT2A (0.69) | KMT2AALDH1A1SMN1; SMN2DPP4DPP7 | |
| SCHEMBL10194548 | 0.83 | SFRP1 (0.56) | KMT2AALDH1A1SMN1; SMN2DPP4DPP7 | |
| SCHEMBL27917838 | 0.81 | BCHE (0.65) | ALDH1A1F10F2 | |
| SCHEMBL10194565 | 0.81 | SFRP1 (0.60) | KMT2AALDH1A1SMN1; SMN2DPP4DPP7 | |
| SCHEMBL13954121 | 0.81 | CCR8 (0.79) | KMT2AALDH1A1SMN1; SMN2CCR8 | |
| SCHEMBL23052423 | 0.81 | KMT2A (0.66) | KMT2AALDH1A1SMN1; SMN2PARGL3MBTL1 | |
| SCHEMBL23052375 | 0.81 | KMT2A (0.63) | KMT2AALDH1A1SMN1; SMN2DPP4DPP7 | |
| SCHEMBL14834383 | 0.80 | MGLL (0.57) | KMT2AALDH1A1SMN1; SMN2DPP4DPP7 | |
| SCHEMBL8546806 | 0.80 | AKR1C3 (0.51) | KMT2AALDH1A1SMN1; SMN2AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513237-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-08-20 | — | — | US | disclosed |
| CN-103068797-A | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | SANOFI SA | 2013-04-24 | — | — | CN | disclosed |
| US-20120178741-A1 | Sulfonylamino-Derivatives As Novel Inhibitors Of Histone Deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-12 | — | — | US | disclosed |
| US-8163733-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-24 | — | — | US | disclosed |
| US-20100234353-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-16 | — | — | US | disclosed |
| US-7767679-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-03 | — | — | US | disclosed |
| EP-1485354-B1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-28 | — | — | EP | disclosed |
| US-20050171347-A1 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-04 | — | — | US | disclosed |
| EP-1485354-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076401-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234353-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | KMT2A 29/4885ALDH1A1 1350/4885SMN1; SMN2 3807/4885 |
| US-20050171347-A1 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | KMT2A 29/4885ALDH1A1 1350/4885SMN1; SMN2 3807/4885 |
| US-20120178741-A1 | Sulfonylamino-Derivatives As Novel Inhibitors Of Histone Deacetylase | HDAC1, HDAC3, HDAC11 | KMT2A 29/4885ALDH1A1 1350/4885SMN1; SMN2 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.